Subtyping EGFR-mutated NSCLC Patients with Adjuvant TKIs or Chemotherapy Using Deep Radiomic Signatures

被引：0
|
作者：
Qi, Y. -F. [1 ,2 ]
Li, J. [3 ]
Qiu, Z. -B. [1 ,2 ]
Wu, Y. -L. [1 ,2 ]
Zhang, X. [3 ]
Zhong, W. -Z. [1 ,2 ]
机构：
[1] Southern Med Univ, Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China
[2] South China Univ Technol, Guangzhou, Peoples R China
[3] Tsinghua Univ, Beijing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Non-small cell lung cancer; Epidermal growth factor receptor; Radiomics;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.01-01
引用
收藏
页码：S565 / S566
页数：2
相关论文
共 50 条
  • [1] Chemotherapy in EGFR-mutated NSCLC: optimizing combinations with TKIs and amivantamab
    Rafael Rosell
    María González-Cao
    Nature Reviews Clinical Oncology, 2024, 21 : 169 - 170
  • [2] Chemotherapy in EGFR-mutated NSCLC: optimizing combinations with TKIs and amivantamab
    Rosell, Rafael
    Gonzalez-Cao, Maria
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (03) : 169 - 170
  • [3] Osimertinib with Chemotherapy in EGFR-Mutated NSCLC
    van Doorn-Khosrovani, Sahar Barjesteh van Waalwijk
    Badrising, Sushil K.
    Burgers, Sjaak
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (05): : 478 - 479
  • [4] Dynamic Evaluation of Circulating miRNA Profile in EGFR-Mutated NSCLC Patients Treated with EGFR-TKIs
    Leonetti, Alessandro
    Capula, Mjriam
    Minari, Roberta
    Mazzaschi, Giulia
    Gregori, Alessandro
    El Hassouni, Btissame
    Papini, Filippo
    Bordi, Paola
    Verze, Michela
    Avan, Amir
    Tiseo, Marcello
    Giovannetti, Elisa
    CELLS, 2021, 10 (06)
  • [5] Disease Monitoring of EGFR-mutated NSCLC Patients Treated with TKIs via EGFR Status in Circulating ctDNA
    Li, Y.
    Xu, Z.
    Wang, S.
    Zhu, Y.
    Ma, D.
    Mu, Y.
    Ying, J.
    Xing, P.
    Li, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S445 - S445
  • [6] Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
    Planchard, D.
    Janne, P. A.
    Cheng, Y.
    Yang, J. C. -H.
    Yanagitani, N.
    Kim, S-W
    Sugawara, S.
    Yu, Y.
    Fan, Y.
    Geater, S. L.
    Laktionov, K.
    Lee, C. K.
    Valdiviezo, N.
    Ahmed, S.
    Maurel, J-M
    Andrasina, I
    Goldman, J.
    Ghiorghiu, D.
    Rukazenkov, Y.
    Todd, A.
    Kobayashi, K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (21): : 1935 - 1948
  • [7] Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: predicting survival and toxicity
    Jokic, Vera
    Savic-Vujovic, Katarina
    Spasic, Jelena
    Stanic, Nemanja
    Marinkovic, Mladen
    Radosavljevic, Davorin
    Cavic, Milena
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (06) : 673 - 679
  • [8] Neoadjuvant Durvalumab plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable EGFR-mutated NSCLC (AEGEAN)
    He, J.
    Gao, S.
    Reck, M.
    Harpole, D.
    Mitsudomi, T.
    Taube, J. M.
    Lee, K. -Y.
    Horio, Y.
    Runglodvatana, Y.
    Aperghis, M.
    Doherty, G. J.
    Laud, P. J.
    Fouad, T. M.
    Heymach, J. V.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S72 - S73
  • [9] EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
    Liu, Ao
    Wang, Xiaoming
    Wang, Lian
    Zhuang, Han
    Xiong, Liubo
    Gan, Xiao
    Wang, Qian
    Tao, Guanyu
    BMC CANCER, 2024, 24 (01)
  • [10] Neoadjuvant Osimertinib with/without Chemotherapy versus Chemotherapy in Patients with EGFR-mutated resectable NSCLC: NeoADAURA
    Griesinger, F.
    Tsuboi, M.
    Weder, W.
    Escriu, C.
    Blakely, C.
    He, J.
    Dacic, S.
    Yatabe, Y.
    Zeng, L.
    Walding, A.
    Chaft, J.
    PNEUMOLOGIE, 2021, 75 : S6 - S7
12345